Latest news with #CBInsights'
Business Wire
5 days ago
- Business
- Business Wire
Massive Bio Recognized in Two Key Categories on CB Insights' AI Drug Research & Development Market Map
CHICAGO--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights' latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio's innovative contributions to revolutionizing cancer care through advanced artificial intelligence solutions. "Being recognized in two critical categories by CB Insights is a testament to the power of AI in transforming oncology care." Share CB Insights' market map highlights companies at the forefront of leveraging AI to accelerate drug discovery and development. Massive Bio's inclusion in both the 'Clinical Trial Matching' and 'Patient Recruitment' categories reflects its dual impact on streamlining clinical trial processes and enhancing patient access to cutting-edge therapies. 'Being recognized by CB Insights in two critical categories is a testament to our team's dedication to transforming oncology care,' said Selin Kurnaz, PhD, CEO and Co-Founder of Massive Bio. 'Our AI-driven platform is designed to bridge the gap between patients and clinical trials, ensuring that individuals receive the most appropriate and timely treatments available.' Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical Officer, added, 'This acknowledgment validates our commitment to integrating advanced AI technologies into clinical workflows. By optimizing trial matching and patient recruitment, we're not only improving operational efficiencies but also enhancing patient outcomes in oncology.' This recognition from CB Insights follows a milestone presence at ASCO25, where Arturo Loaiza-Bonilla presented a poster session on AI-powered clinical trial matching and participated in the ASCO/ESMO Joint Session, emphasizing international collaboration in oncology innovation. In addition, Selin Kurnaz was named a PCC Wayfinder, honoring her leadership in advancing equitable access and data-driven transformation in cancer care. Massive Bio's platform utilizes sophisticated algorithms and real-time data analytics to match cancer patients with suitable clinical trials, considering factors such as genetic profiles, treatment histories, and geographic locations. This approach has significantly increased trial enrollment rates and reduced the time required to identify eligible participants. The company's dual recognition by CB Insights highlights its comprehensive approach to addressing challenges in clinical trial enrollment and patient engagement. As the demand for personalized cancer treatments grows, Massive Bio continues to lead in providing scalable, AI-driven solutions that connect patients with life-saving clinical trials. About Massive Bio Massive Bio, co-founded by , Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit
Business Wire
7 days ago
- Business
- Business Wire
CB Insights Announces Collaboration with Snowflake to Make Market Intelligence Accessible to AI and Agents in Real Time
SAN FRANCISCO--(BUSINESS WIRE)--CB Insights, the leading provider of predictive market intelligence, today announced at Snowflake's annual user conference, Snowflake Summit 2025, a collaboration with Snowflake, the AI Data Cloud company. Through this collaboration, CB Insights' continuously validated data on more than 10 million companies, 1,500 tech markets, and how they all compare is now available via the Snowflake Marketplace. Joint customers can now simply 'point and click' to use the data in their AI, agents, dashboards, and other enterprise applications. 'To build agents and AI that are effective, enterprises need more than internal data—they need reliable, structured context about what's happening in the world outside their four walls,' said Manlio Carrelli, CEO of CB Insights. 'To build agents and AI that are effective, enterprises need more than internal data—they need reliable, structured context about what's happening in the world outside their four walls,' said Manlio Carrelli, CEO of CB Insights. 'We provide that external intelligence layer: on the markets you're in, the competitors you're up against, the companies you should buy, partner with, or learn from. Our collaboration with Snowflake makes embedding that context in your AI, dashboards and enterprise apps as simple as a few clicks.' 'The best AI outcomes come from the best data,' said Kieran Kennedy, VP, Data Cloud Product Partners, Snowflake. 'CB Insights delivers high-quality, context-rich data that helps our joint customers act faster and smarter. We're excited to welcome them to the Snowflake Marketplace—and to use their terminal ourselves to improve our own decision-making.' By combining CB Insights' proprietary external intelligence with Snowflake's secure, data and AI platform, the two companies enable powerful use cases: Improved LLM accuracy by training on validated data about companies and technologies Increased the effectiveness of AI agents by giving them 'world context' about what's happening outside your company's four walls in the companies and markets you care about Enriched dashboards and workflows for business functions. For example, a business development dashboard can include insight into competitor business relationships or AI-generated SWOT analyses on prospective partners. Unlike traditional market intelligence databases, CB Insights' dataset is built through a proprietary 'double validation' pipeline that uses machine learning to continuously analyze and confirm data on management teams, fundings, partnerships, deals, earnings calls, investor activity, hiring patterns, patents and more—transforming global business activity into structured, decision-ready signals. The CB Insights-Snowflake integration allows joint customers to simply 'point' to CB Insights data and make it instantly and securely available to their internal applications built on Cortex AI —without having to move the data. This allows enterprises to avoid manual ETL (Extract, Transform, Load) pipelines and API complexity. Key benefits: Ready for AI and BI: Use CB Insights data in agents, LLMs, dashboards, and planning tools. Trusted, Validated Signals: Make better decisions with continuously verified insights into markets, competitors, and technologies. Faster Time-to-Value: Eliminate ETL and adoption friction—activate the data in minutes via Snowflake Marketplace. To learn more about the CB Insights-Snowflake collaboration, visit Headquartered in New York City, CB Insights is the leading provider of AI for market intelligence. The company aggregates, validates, and analyzes hard-to-find private and public company data. Its powerful AI tells users what it all means to them personally. The world's smartest companies rely on CB Insights to focus on the right markets, stay ahead of competitors, and identify the right targets for sales, partnership, or acquisition. Visit for more information.
